Enzyre Announces Founder and CEO’s Transition

Nijmegen, November 1, 2023 – Enzyre, a startup company focused on blood coagulation management by developing point-of-care IVD solutions, announces a significant change in its leadership. Cofounder and CEO Guido Maertens has decided to step down as CEO of the company. Guido has played an instrumental role in the foundation and growth of Enzyre since its inception almost eight years ago. Under his leadership, Enzyre has transformed into an important player in the point-of-care IVD industry for blood coagulation monitoring, pioneering innovative solutions that have the potential to revolutionize the field blood coagulation disease management.

During his tenure, Guido successfully navigated Enzyre through a series of important milestones, including the completion of the EUR 12 million Series A financing round and securing strategic partnerships with key industry players such as Takeda Inc.

As Guido steps down from his role as CEO, the company expresses its gratitude for his leadership, guidance, and unwavering commitment to the mission of Enzyre.

Enzyre will commence the search for a new CEO, and has recruited interim CEO Roald van Noort to ensure a seamless handover. The supervisory board, along with co-founder and CSO Waander van Heerde, will work closely to identify the best candidate to lead Enzyre into its next phase of growth and innovation.

Guido commented: “It has been an incredible journey to lead Enzyre from its inception to where it stands today. I am proud of what we have achieved and am confident that the company is well-positioned for an even brighter future. I am excited to see the company continue to thrive.”

Enzyre remains committed to its mission of improving patient care through innovative IVD solutions. The company will continue its operations without interruption, and partners and stakeholders can expect the same level of quality and commitment they have come to know and trust.

For more information about Enzyre and its products, please visit the company’s website at www.enzyre.com.